Journal Information
Vol. 42. Issue 4.
Pages 206 (April 2006)
Share
Share
Download PDF
More article options
Vol. 42. Issue 4.
Pages 206 (April 2006)
Letters to the Editor
Full text access
Bronchiectasis and Macrolides
Visits
3803
M. Vila-Justriboa, J. Dorca-Sargatalb, S. Bello-Drondac
a Hospital Arnau de Vilanova, Lleida, Spain
b Hospital de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain
c Hospital Miguel Servet, Zaragoza, Spain
This item has received
Article information
Full text is only aviable in PDF
REFERENCES
[1]
L Máiz Carro.
Tratamiento con azitromicina a largo plazo en un paciente con bronquiectasias idiopáticas.
Arch Bronconeumol., 41 (2005), pp. 295-296
[2]
A Jaffe, A Bush.
Anti-inflammatory effects of macrolides in lung disease.
Pediatr Pulmonol., 31 (2001), pp. 464-473
[3]
N Oligaki.
Bacterial biofilm in chronic airway infection.
Kasenshogaku Zasshi., 68 (1994), pp. 138-151
[4]
GW Amsden.
Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?.
J Antimicrob Chemother., 55 (2005), pp. 10-21
[5]
BK Rubin, MO Henke.
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
Chest, 125 (2004), pp. 70-78
[6]
P Scheinberg, E Shore, on behalf of the PC-TNDS-008 Study Group.
A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.
Chest, 127 (2005), pp. 1420-1426
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?